Perception of Risk through Phases of Drug Research and Development: Questionnaire Survey

Cowlrick, Ivor; Wolf, Roland; Hedner, Thomas; Olausson, Michael

doi:10.1177/009286150904300510

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proportion of the responders who worked for a small organization with <50 employees was 28% with a similar proportion of 30% who worked with a large organization >5,000 employees. The specifics of questionnaire development, demographics, study population, and data collection have been previously published (Cowlrick et al., ). Characteristics collected from the study population in the present study are shown in Table .…”

Section: Methods and Datamentioning

confidence: 99%

Decision‐making in the pharmaceutical industry: analysis of entrepreneurial risk and attitude using uncertain information

et al. 2011

Self Cite

View full text Add to dashboard Cite

The main purpose of this study was to investigate judgments made by employees from the pharmaceutical industry and allied health‐care sectors in a set of four different drug discovery and development cases derived from real scenarios. Each case study related to go/no‐go decisions taken from various steps in drug discovery through preclinical and clinical development (investigational new drug) on to market introduction (new drug application) and treatment of the target population. Using a web‐based questionnaire, 52 respondents made five sets of judgment within each drug case whether to continue or halt further project development. For each case, additional details of the developmental scenario were disclosed to the respondent after completion of each judgment response. We also assessed to what extent the individual judgments given by the respondents were influenced by work experience and functional role, education, or their perceived entrepreneurial character. Our study demonstrates that health‐care employees differ substantially in their individual intuitive judgments of benefit and risk in go/no‐go decisions during the drug discovery and development process. This lack of coherence and wide variability with respect to the drug development cases selected may reflect judgment in the real world. Such judgments are usually taken from incomplete information, and individual decision‐making rules vary substantially between experts in the field. Further knowledge about this inherent human functional judgment variability may be helpful to form a better understanding of individual decision‐making in relation to inherent uncertainties. Additional research may also clarify how personal experience within drug discovery and development influences judgment and help to optimize decision outcomes in the drug development sector. Importantly, a deeper insight of the fundamentals and rules that shape individual and group decision‐making of everyday drug discovery and development may help to optimize the decision processes in the pharmaceutical industry.

show abstract

Section: Methods and Datamentioning

confidence: 99%

Decision‐making in the pharmaceutical industry: analysis of entrepreneurial risk and attitude using uncertain information

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…The questionnaire used for this study was developed by revising and complementing questionnaires of other studies, based on in-depth interviews with 6 (six) multi-stakeholders involved in drug development field, representing governments and pharmaceutical industries [19–22,27–31]. The questionnaire was composed of 47 questions on pharma capabilities and 19 questions on innovation incentives.…”

Section: Methodsmentioning

confidence: 99%

Gap analysis for drug development policy-making: An attempt to close the gap between policy and its implementation

Siagian

Ayuningtyas

2019

PLoS ONE

View full text Add to dashboard Cite

Introduction Most drug development policies in developing countries are enacted without achieving the desired results. This study aims to determine the prioritization of drug development in Indonesia through the evidence-based policymaking process in order to close the distance between stated policy goals and the realization of planned goals. Methods A quantitative approach in the form of cross-sectional research using a structured survey was adopted and validated using a set of techniques involved in the calculation of a structural equation model. An independent samples t-test was used to test the significance of the differences between two views: pharmaceutical industries and the government of Indonesia. Findings The study reveals that pharmaceutical industries and governments were highly consistent in their perceived challenges in facing the drug development. It also reveals drivers and weaknesses of drug development, including market opportunities, push-pull-regulatory pull factors and regulation, as priorities for improvement. Conclusions Gap analysis based on a structural model was borne out to address gap challenges between policy and its implementation, with the use of evidence-based policymaking.

show abstract

Perception of Risk through Phases of Drug Research and Development: Questionnaire Survey

Cited by 2 publications

References 7 publications

Decision‐making in the pharmaceutical industry: analysis of entrepreneurial risk and attitude using uncertain information

Decision‐making in the pharmaceutical industry: analysis of entrepreneurial risk and attitude using uncertain information

Gap analysis for drug development policy-making: An attempt to close the gap between policy and its implementation

Contact Info

Product

Resources

About